ABBV vs CVX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Chevron Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Chevron Corporation · Energy
$193.33
-18.2% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
CVX trades at a lower forward P/E
(31.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CVX |
| Current Price |
$197.69 |
$193.33 |
| Fair Value Estimate |
$210.22 |
$158.09 |
| Upside to Fair Value |
+6.3%
|
-18.2%
|
| Market Cap |
$349.7B |
$385.8B |
| Forward P/E |
83.3x
|
31.3x
|
| EV / EBITDA |
23.4x
|
10.3x
|
| Price / Sales |
5.7x
|
2.1x
|
| Price / FCF |
18.7x
|
23.8x
|
| Revenue Growth YoY |
+10.0%
|
-5.3%
|
| Gross Margin |
70.2%
|
30.4%
|
| Operating Margin |
26.7%
|
9.0%
|
| Return on Equity |
-361.6%
|
7.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
4.19%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Chevron Corporation operates as a leading integrated oil and gas company with significant upstream and downstream operations. The company benefits from experienced leadership under CEO Mike Wirth, who has over 44 years with Chevron, and maintains a strong market position as the second largest Big Oil major by market cap and net profits. However, Chevron currently trades at a very expensive valuat…
Accumulation Zones
| Metric |
ABBV |
CVX |
| Zone Low |
$157.66 |
$118.57 |
| Zone High |
$178.69 |
$134.38 |
| In Buy Zone? |
No
|
No
|